Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Proteomics. Clinical Applications|December 8, 2010
Cancer biomarker discovery via low molecular weight serum proteome profiling - Where is the tumor?Michael T Davis, Paul Auger, Chris Spahr, et al.
Methods (San Diego, Calif.)|February 22, 2005
Informatics for protein identification by mass spectrometryRichard S Johnson, Michael T Davis, J Alex Taylor, et al.
Biomedical Chromatography : BMC|November 9, 2023
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitorMichael T Davis, Nicole M Anders, A Dimitrios Colevas, et al.
Plos One|October 15, 2014
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experienceMichael B Bass, Bin Yao, Yong-Jiang Hei, et al.
Biochemical and Biophysical Research Communications|August 15, 2006
Crucial role of position 40 for interactions of CCK-58 revealed by sequence of cat CCK-58Joseph R Reeve, Grace L Rosenquist, David A Keire, et al.
Proteomics|January 27, 2010
Maximizing the sensitivity and reliability of peptide identification in large-scale proteomic experiments by harnessing multiple search enginesWen Yu, J Alex Taylor, Michael T Davis, et al.
Regulatory Peptides|April 11, 2003
Synthesis of biologically active canine CCK-58Joseph R Reeve, David A Keire, Tamer Coskun, et al.
Regulatory Peptides|April 11, 2003
Rat progastrin processing yields peptides with altered potency at the CCK-B receptorDavid A Keire, S Vincent Wu, David L Diehl, et al.
Pancreas|October 9, 2002
Differences in receptor binding and stability to enzymatic digestion between CCK-8 and CCK-58Joseph R Reeve, Douglas C McVey, Nigel W Bunnett, et al.
The Journal of Clinical Endocrinology and Metabolism|August 27, 2010
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancerMichael B Bass, Steven I Sherman, Martin J Schlumberger, et al.
Pageof 1